

PCMA MEMBER COMPANIES



SPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

February 8 & 9

**JW MARRIOTT ORLANDO GRANDE LAKES
ORLANDO, FL**

CONFERENCE PROGRAM

PARTNERS



PRESIDENTIAL SPONSORS



Please join us in thanking the following companies for their support of this year's sPCMA *Business Forum*

PARTNERS



PRESIDENTIAL SPONSORS



EXECUTIVE SPONSORS



GENERAL SPONSORS



Welcome to the 2016 sPCMA Business Forum

The mission of the sPCMA Business Forum is to be the premier specialty pharmacy business conference. The Forum offers invaluable networking and education for all individuals and companies conducting business in the specialty pharmacy space. We've designed the Business Forum to be an essential component of your annual conference schedule and business strategy.

From an educational standpoint, our speakers are among the industry's top thought leaders. The Business Forum has the highest number of PBM and specialty pharmacy senior executives and decision makers of any industry conference. Conference attendees are provided with unmatched networking opportunities with industry partners and customers.

The ever-evolving specialty pharmacy industry presents a multitude of challenges and opportunities for the health care marketplace. We hope that over the next two days you will learn from, and dialogue with industry experts, peers, and allies.

A few highlights you won't want to miss:

- » **Education:** General Sessions are designed to be strategic in nature and Breakout Sessions drill down into the nuances of more specific industry dynamics.
- » **Networking:** While conference sessions are scheduled all day, we recognize the unique opportunity the Business Forum offers attendees for private meetings and networking.

Sunday, Monday, and Tuesday evening receptions are open to all conference attendees. Member Company Receptions will take place concurrently during lunch Monday and Tuesday. These receptions offer excellent opportunities for interactions between PBM member and drug manufacturers.

Be sure to also spend some time in the JW Marriott Lobby to catch up with old colleagues and make new business connections.

Thank you for coming to this year's sPCMA Business Forum. We hope that you find the conference to be enlightening and beneficial to your business.

Contents

PCMA Board of Directors	2
sPCMA Board of Directors	3
PCMA Staff	4
PCMA Members	5
PCMA Affiliates	6
Meeting Information	7
Private Meeting Room Assignments	8
Hotel Floor Plans and Maps	9
Member Company Receptions	11
PCMA-Connect	12
Conference Agenda	13
Session Details	21
CPE Information	43
Speakers	45
Marketplace Directory	61



PCMA Board of Directors



Chairman, PCMA Board of Directors

Tim Wentworth
President
Express Scripts



Jim DuCharme
President &
Chief Executive Officer
Prime Therapeutics



Mark Thierer
Chief Executive Officer
OptumRx



William Fleming
President, Humana Pharmacy
Solutions
Humana Inc.



Greg Watanabe
President
MedImpact Healthcare
Systems, Inc.



Chris Hovevar
President, Select Segment &
Cigna Pharmacy Management
Cigna Corporation



Bill Wolfe
Vice President, Pharmacy
Aetna



Jon Roberts
President, CVS/caremark &
Executive Vice President
CVS Health



A DIVISION OF THE
Pharmaceutical Care Management Association

sPCMA Board of Directors



Steve Avey
Vice President, Specialty Pharmacy
MedImpact Healthcare Systems, Inc.



Fran Gregory
Director, Specialty Pharmacy Strategy
Humana Pharmacy Solutions



Christopher Bradbury
Senior Vice President, Integrated Clinical Solutions and Specialty Pharmacy
Cigna Pharmacy Management



Alan Lotvin
Executive Vice President, Specialty Pharmacy
CVS Health



Pete Clagett
Senior Vice President, Cost of Care and Specialty
Prime Therapeutics



Bill Martin
Vice President, Accredo Specialty Trade Relations
Express Scripts



Jim Clement
Executive Director, Industry Relations and Financial Strategy
Aetna Pharmacy Management



Michael Zeglinski
Senior Vice President, Specialty Pharmacy
OptumRx

About sPCMA

PBMs administer prescription drug plans for more than 266 million Americans. With the costs and complexity of specialty drug treatments rising, PBMs offer a number of services designed to improve the quality of care for patients across the nation while managing overall costs to the health care system. To encourage complete coordination across the continuum of patient care, payers depend on PBMs' utilization management tools, including the use of specialty pharmacies, to ensure that the value of therapy is optimized, at the most reasonable costs possible.

sPCMA Mission

The rapid and ever-changing growth of the specialty pharmacy industry presents a multitude of challenges and opportunities for the overall health care industry. sPCMA provides leadership and representation to the specialty pharmacy industry on matters of public policy, communications, and the value specialty pharmacies deliver to the health care delivery system. sPCMA:

- » Defines and promotes the value of specialty pharmacy;
- » Illuminates emerging policy issues affecting the industry;
- » Serves as a public voice on matters related to specialty pharmacy; and
- » Provides a forum for members to engage opinion leaders, policymakers, and other authorities.



PCMA Staff

Mark Merritt

President & Chief Executive Officer

April Alexander

Senior Director, State Affairs

Kristin Bass

Senior Vice President, Policy and Federal Affairs

Tim Brogan

Assistant Vice President, Research and Policy

Megan Coder, PharmD

Senior Director, Industry Programs

Andy Cosgrove

Vice President, Policy

Charles Coté

Vice President, Strategic Communications

Clem Cypra

Assistant Vice President, State Affairs

Jenny Dawson

Senior Manager, Conferences and Development

Jonathan Heafitz

Assistant Vice President, Federal Affairs

Ryan Hickey

Director, Accounting and Operations

Greg Johnson

Assistant Vice President, Strategy

Jennifer Joslin

Executive Assistant to the President & CEO

Scott Kipper

Vice President, State Affairs

Wendy Krasner

Vice President, Regulatory Affairs

Barbara Levy

General Counsel

Greg Lopes

Senior Director, Public Affairs

Jessica Mazer, Esq

Assistant Vice President, State Affairs

Brian McCarthy

Chief Operating Officer

Anne McCraw

Senior Director, Industry Relations

Brenda Palmer

Chief Financial Officer

Kristen Pumphrey

Senior Director, Conferences

Meagan Riordan

Director, State Affairs

Deloris Tinsley

Executive Assistant

Scott Woods

Senior Director, Policy

We have moved. Please note our new address.

PCMA
325 7th Street, NW | 9th Floor
Washington, DC 20004
www.pcmnet.org | www.spcma.org

PCMA Members

aetna[®]

 **Cigna**[®]

 **CVS**Health

 **EXPRESS SCRIPTS**[®]

Humana
Pharmacy Solutions.


integrated pharmacy services

Mediimpact

Meridian  **Rx**

 **OPTUMRx**[™]

 **PRIME**
THERAPEUTICS[®]

USscript



PCMA Affiliates

abbvie ACADIA[®] Pharmaceuticals ACORDA[®] THERAPEUTICS ACTELION Alcon
 Alkermes[®] Allergan AMARIN AMGEN[®] Apobiologix
 astellas AstraZeneca AVANIR[®] pharmaceuticals Baxalta
 MedImmune
 Bayer HealthCare Pharmaceuticals Biogen Boehringer Ingelheim Bristol-Myers Squibb Company
 Celgene COLLEGIUM Pharmaceutical covermymeds Daiichi-Sankyo Depomed[®]
 Dexcom[®] CONTINUOUS GLUCOSE MONITORING DK PIERCE Eisai EMD Serono Living science, transforming lives endo
 FRESINIUS MEDICAL CARE Genentech A Member of the Roche Group genzyme GILEAD gsk GlaxoSmithKline
 GRIFOLS HealthStrategiesGroup Incyte INDIVIOR Focus on you.
 Infinity[™] PHARMACEUTICALS Johnson & Johnson HEALTH CARE SYSTEMS INC. kaléo KERYX BIOPHARMACEUTICALS, INC. Kowa Kowa Pharmaceuticals America, Inc.
 Lilly Lundbeck LUNG BIOTECHNOLOGY Mallinckrodt Pharmaceuticals
 medac PHARMA MEDIVATION[™] Driven by science. Focused on life. MERCK Mylan[®] NOVARTIS
 noven THERAPEUTICS, LLC novo nordisk[®] Otsuka Otsuka America Pharmaceutical, Inc. PERNIX[™] THERAPEUTICS
 Pfizer PRECISION FOR VALUE PURDUE[®] REGENERON SANDOZ
 SANOFI Shire SUN PHARMA SUNOVION Synergy Pharmaceuticals
 Takeda TEVA TEVA PHARMACEUTICALS ucb United Therapeutics CORPORATION UPSHER-SMITH Pharmaceuticals Since 1919
 VALEANT Pharmaceuticals International, Inc. VERTEX ViiV Healthcare VIKING HEALTHCARE SOLUTIONS XenoPort[™]

sPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

Meeting Information

We Make Quality Healthcare Accessible

Teva Pharmaceuticals is working every day to make quality healthcare accessible around the world. As a manufacturer of specialty and generic pharmaceuticals, Teva provides both new therapies and greater access to quality, affordable medicines.



TEVA

tevausa.com

Meeting Information

Registration

All conference attendees are required to check in at the PCMA Registration Desk located in the *Mediterranean Foyer* of the JW Marriott.

Sunday, February 7 4:00 pm – 6:30 pm

Monday, February 8 6:30 am – 6:00 pm

Tuesday, February 9 6:30 am – 4:00 pm

Name badges and conference materials will be available for pick-up during the hours listed above. Photo identification must be presented in order to collect materials.

Purple badges indicate drug manufacturers. Beige badges indicate PBM, payer, specialty pharmacy, and other industries.

If you require a copy of your registration confirmation, receipt of payment, or invoice, please email Jenny Dawson at jdawson@pcmanet.org.

Security

Conference participants **MUST** wear badges when attending any conference function, including sessions, meals, evening receptions, and private meetings in member and sponsor meeting room facilities. Event security will monitor entrances to all conference activities. Please do not misplace or forget badges, as duplicates will not be provided.

Attire

Attire for all conference activities is business casual. Some evening receptions will be held outdoors. Please be prepared for cooler temperatures.

Internet

Wi-Fi is not available in the Conference Center or in private meeting rooms, but it can be accessed while in the lobby and other public spaces.

Presentations

Presentations authorized for distribution will be posted online after the conference. Attendees will be notified by email once presentations are available.

Photography

Professional photographs taken during the conference may be posted online and/or printed in future materials.

Mobile/Smartphone Policy

As a courtesy to presenters and fellow attendees, phones should be turned to silent during all conference functions. Please minimize use during conference sessions.

Disclaimer

The opinions expressed by program participants are those of the individual presenters. They do not necessarily reflect the views of PCMA or its members.

Attendance at a Pharmaceutical Care Management Association (PCMA) meeting or event includes the limited, non-exclusive, revocable, and non-transferable right and license to use any PCMA materials, whether written, oral or electronic, made available by PCMA to the attendees for informational or personal use purposes only. PCMA reserves all other rights. PCMA or its licensors own all rights in and to all of its presentations, content, designs, methodologies, processes, programs, products, information, and documentation. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION, PCMA and all other names, logos, and icons identifying PCMA and its products and services are proprietary trademarks of PCMA, and any use of such marks without the express written permission of PCMA is strictly prohibited.



Private Meeting Room Assignments

All private meeting room assignments are listed below. To help you locate these rooms, we have provided floor plans and a resort map on the following pages. Please note that anyone entering meeting rooms must be registered for the conference and wearing a badge.


Contact Jenny Dawson, jdawson@pcmanet.org, or check in at the PCMA Registration Desk with any questions related to private meeting space.

Partner & Presidential Sponsors	Meeting Room	Room Location
AbbVie	14007	Executive Suite, 14th Floor
Allergan	14019	Executive Suite, 14th Floor
Astellas	Cordova 4	Conference Center
AstraZeneca	14058	Executive Suite, 14th Floor
Biogen	Milagro Boardroom	Conference Center
Boehringer Ingelheim	12007	Executive Suite, 12th Floor
Celgene	Cordova 2	Conference Center
CoverMyMeds	12019	Executive Suite, 12th Floor
EMD Serono, Inc.	Marbella 3	Conference Center
Genentech	12058	Executive Suite, 12th Floor
Johnson & Johnson	Cordova 3	Conference Center
Lilly USA, LLC	Segura 5	Conference Center
Novartis	15007	Executive Suite, 15th Floor
Novo Nordisk	La Serena Boardroom	Conference Center
Sanofi	15019	Executive Suite, 15th Floor
Sunovion	15058	Executive Suite, 15th Floor
Teva	Marbella 4	Conference Center

Executive & General Sponsors	PCMA Member Companies	Room Location
Actelion	Aetna	<p>Companies to the left have access to private but shared rooms located on the lower level of the JW Marriott Conference Center.</p> <p>Be sure to confirm the name of your meeting room with the meeting organizer.</p> <p>Please begin and end meetings in shared rooms on time. Another meeting might immediately precede or follow yours.</p>
Baxalta	Cigna	
Bayer	CVS Health	
Genzyme	Express Scripts	
Gilead	Humana Pharmacy Solutions	
Mallinckrodt	LDI Integrated Pharmacy Services	
Medivation	MedImpact	
Merck	MeridianRx	
Mylan	OptumRx	
Otsuka	Prime Therapeutics	
Pfizer	US Script	
Purdue Pharma		
Regeneron		
Takeda		
UCB		
Valeant		
Vertex		
XenoPort		

Hotel Floor Plans and Maps

HOTEL FLOOR PLANS AND MAPS





Member Company Receptions

Monday & Tuesday, February 8 & 9
12:00 pm – 1:30 pm

Select PCMA members host receptions exclusively for conference attendees from the drug manufacturer industry (designated by a purple badge). These Member Company Receptions bring together all attendees from each PBM host company and offer excellent opportunities for networking and one-on-one interactions between PBM, specialty pharmacy, and pharma executives.

This year's Member Company Receptions will take place concurrently during lunch on Monday and Tuesday, from 12:00 pm until 1:30 pm. Each participating company will host a reception on one of the two days.


Lunch will be served in various reception rooms. Manufacturer attendees will be able to flow in and out of each reception while individuals with companies not hosting or attending one of the receptions are welcome to eat and network in the *Mediterranean Porte-Cochère*. Please note that in addition to manufacturers, only employees of the host company are allowed in their respective reception rooms.

Monday

- Aetna** — *Palazzo FGH*
- Humana** — *Mediterranean 2/3*
- OptumRx** — *Palazzo D*

Tuesday

- CVS Health** — *Palazzo FGH*
- Express Scripts** — *Palazzo D*
- Prime Therapeutics** — *Mediterranean 2/3*





PCMA-Connect

PCMA-Connect is an private LinkedIn Group and online networking community for PCMA members, affiliates, and registered conference attendees.

Search LinkedIn for “*PCMA-Connect*” to join the Group now.

As those familiar with sPCMA conferences know, our sessions address the most current and relevant industry issues, and our business networking opportunities are unmatched. *PCMA-Connect* offers additional business networking throughout the year through online networking.

PCMA-Connect allows you to:

- » Network with other engaged industry stakeholders, build your network, message with other group members, and coordinate meetings;
- » Start online discussions about hot industry topics; and
- » Learn about the latest PCMA, sPCMA, and conference developments.

Visit sPCMA's New Facebook Page



While there...

- » See pictures from this year's *Business Forum*
- » View pictures from past sPCMA events
- » Get updates on CPE credit status
- » Learn about other PCMA conferences and upcoming events
- » Be the first to know about sPCMA new website features, papers, and articles

Like us at facebook.com/spcmaorg



A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

AGENDA & SESSION DETAILS

Agenda & Session Details

a century of innovation

Nearly 100 years ago, Nobel Prize-winning scientist August Krogh and his wife Marie embarked on a journey to revolutionize diabetes care, driven by her needs as a diabetes patient. Today, Novo Nordisk still takes a deeply human approach to everything we do. As a world leader in diabetes care, we are in a position of great responsibility. We must continue to combine drug discovery and technology to turn science into treatments. We must prioritize research, education, and partnerships around the world to make diabetes a global priority. We must conduct our business responsibly in every way. And most importantly, we can never lose sight of the patient-centric approach that has driven our vision of innovation since our inception.

**Together, we can defeat
diabetes in our lifetime.**

For more about us, visit novonordisk.us



Conference Agenda

Sunday, February 7

4:00 pm – 6:30 pm	Registration Open	<i>Mediterranean Foyer</i>
6:30 pm – 10:30 pm	Super Bowl Party	<i>Valencia Lawn</i>

Monday, February 8

6:30 am – 6:00 pm	Registration Open	<i>Mediterranean Foyer</i>
7:00 am – 6:00 pm	Private Meeting Rooms Open & Networking in the Lobby throughout the Day <i>Please reference pages 8–9 for room assignments and locations</i>	
7:30 am – 9:00 am	Networking Breakfast	<i>Mediterranean Porte-Cochère</i>
9:00 am – 9:30 am	BREAKOUT SESSIONS <i>(two concurrent)</i>	
	CEUs: 0.050 Indication-Based Pricing in Oncology Mary Dorholt, <i>Senior Director & Specialty Clinical Practice Lead</i> Express Scripts	<i>Palazzo E</i>
	CEUs: 0.050 PBMs Prepare for Biosimilars — How PBMs are Preparing for an Expansion of the Biosimilar Market Steve Avey, <i>Vice President, Specialty Pharmacy</i> , MedImpact	<i>Palazzo ABC</i>
9:30 am – 9:45 am	Break	<i>Palazzo & Mediterranean Foyers</i>
9:45 am – 10:15 am	BREAKOUT SESSIONS <i>(two concurrent)</i>	
	CEUs: 0.050 Strategic Changes in Medicare Part D Michael Anderson, <i>Chief Pharmacy Officer</i> , UnitedHealthcare Medicare & Retirement	<i>Palazzo E</i>
	CEUs: 0.050 An Analyst's Perspective on Market Dynamics — Future of the Formulary, Biosimilars, and Specialty Pharmacies Ronny Gal, <i>Senior Analyst</i> , <i>Global Specialty Pharmaceuticals</i> Sanford Bernstein	<i>Palazzo ABC</i>
10:15 am – 10:30 am	Break	<i>Palazzo & Mediterranean Foyers</i>



Monday, February 8 *(continued)*

10:30 am – 11:15 am	GENERAL SESSION Conference Moderator: Betty Nguyen, <i>Journalist & Anchor</i> NBC News and MSNBC Drug Pricing and Affordability Challenges for Payers and Policymakers Everett Neville, <i>Senior Vice President, Supply Chain</i> Express Scripts Steve Pearson, <i>President, Institute for Clinical and Economic Review</i> Moderator: Sam Nussbaum, <i>Former Executive Vice President Clinical Health Policy & Chief Medical Officer, Anthem</i>	<i>Mediterranean 4/5</i>
11:15 am – 12:00 pm	GENERAL SESSION Defining and Differentiating Specialty Pharmacies Bill Martin, <i>Vice President, Accredo Specialty Trade Relations</i> Express Scripts Michael Zeglinski, <i>Senior Vice President, Specialty Pharmacy</i> OptumRx Moderator: Adam Fein, <i>President, Pembroke Consulting</i>	<i>Mediterranean 4/5</i>
12:00 pm – 1:30 pm	Member Company Lunch Receptions <i>For PBM members and manufacturers only</i> » Aetna — <i>Palazzo FGH</i> » Humana — <i>Mediterranean 2/3</i> » OptumRx — <i>Palazzo D</i>	
	Networking Lunch for All Others	<i>Mediterranean Porte-Cochère</i>
1:30 pm – 2:00 pm	BREAKOUT SESSIONS <i>(two concurrent)</i>	
	CEUs: 0.050 The Role of Copay Coupons in Specialty Pat Gleason, <i>Director, Health Outcomes, Prime Therapeutics</i>	<i>Palazzo E</i>
	CEUs: 0.050 The Intersection of Oncology Pathways and Value Measures — The Impact on Payers, Providers, Pharma, and Patients Debbie Stern, <i>Senior Vice President, Strategy and Business Development, Medical Oncology and Specialty Pharmacy</i> eviCore Healthcare	<i>Palazzo ABC</i>
2:00 pm – 2:15 pm	Break	<i>Palazzo & Mediterranean Foyers</i>

Monday, February 8 *(continued)*

2:15 pm – 2:45 pm	BREAKOUT SESSIONS <i>(two concurrent)</i>	
CEUs: 0.050	The 340B Program's Impact on the Specialty Pharmacy Industry Stephanie Hales, <i>Partner</i> , Sidley Austin LLP	<i>Palazzo E</i>
CEUs: 0.050	2015 Specialty Pharmacy Patient Satisfaction Survey Results Jason Rucker, <i>Director, Trade Research</i> , Zitter Health Insights	<i>Palazzo ABC</i>
2:45 pm – 3:00 pm	Break	<i>Palazzo & Mediterranean Foyers</i>
3:00 pm – 3:30 pm	BREAKOUT SESSION	
CEUs: 0.050	Separating Facts and Myths with Specialty Drug Management Under the Medical Benefit — An Integrated PBM/Specialty Pharmacy Perspective Thom Stambaugh, <i>Vice President</i> , Cigna Specialty Pharmacy Services	<i>Palazzo ABC</i>
3:30 pm – 3:45 pm	Break	<i>Palazzo & Mediterranean Foyers</i>
3:45 pm – 4:15 pm	BREAKOUT SESSION	
CEUs: 0.050	The Role of Drug Pipeline Data and Analytics in Payer Decision Making Farrah Wong, <i>Manager, Pipeline and Drug Surveillance</i> , OptumRx	<i>Palazzo ABC</i>
6:30 pm – 10:00 pm	Cocktail and Dinner Reception	<i>Valencia Lawn & Terrace</i>



Tuesday, February 9

6:30 am – 4:00 pm	Registration Open	<i>Mediterranean Foyer</i>
7:00 am – 4:00 pm	Private Meeting Rooms Open & Networking in the Lobby throughout the Day <i>Please reference pages 8–9 for room assignments and locations</i>	
7:30 am – 9:00 am	Networking Breakfast	<i>Mediterranean Porte-Cochère</i>
9:00 am – 9:30 am	GENERAL SESSION Opening Remarks Mark Merritt, <i>President & Chief Executive Officer</i> , PCMA PBM Industry Keynote Address: State of the Industry — New Challenges for All of Us Tim Wentworth, <i>President</i> , Express Scripts	<i>Mediterranean 4/5</i>
9:30 am – 10:15 am	GENERAL SESSION Evolving Oncology Drug Management Programs — Prior Authorization, Comparative Effectiveness Displays, Performance Contracting, and a New Episode Payment Program Lee Newcomer, <i>Senior Vice President, Oncology, Genetics and Women’s Health</i> , UnitedHealthcare	<i>Mediterranean 4/5</i>
10:15 am – 11:00 am	GENERAL SESSION The Latest Trends in Drug Product Utilization Doug Long, <i>Vice President, Industry Relations</i> , IMS Health	<i>Mediterranean 4/5</i>
11:00 am – 11:15 am	Break	<i>Palazzo & Mediterranean Foyers</i>
11:15 am – 12:00 pm	BREAKOUT SESSIONS <i>(two concurrent)</i>	
CEUs: 0.075	The Value of Specialty Drugs Across the Health Care Continuum Martin Zagari, <i>Vice President, Global Health Economics</i> , Amgen	<i>Palazzo E</i>
CEUs: 0.075	The Role and Scope of IDN and ACO Specialty Pharmacies Bill Roth, <i>Founding Partner</i> , Blue Fin Group	<i>Palazzo ABC</i>


Tuesday, February 9 *(continued)*

12:00 pm – 1:30 pm	Member Company Lunch Receptions <i>For PBM members and manufacturers only</i> <ul style="list-style-type: none"> » CVS Health — <i>Palazzo FGH</i> » Express Scripts — <i>Palazzo D</i> » Prime Therapeutics — <i>Mediterranean 2/3</i> 	
	Networking Lunch for All Others	<i>Mediterranean Porte-Cochère</i>
1:30 pm – 2:00 pm	BREAKOUT SESSIONS <i>(two concurrent)</i>	
	CEUs: 0.050 Personalized Medicine in Oncology Care	<i>Palazzo E</i>
	Mike Kolodziej, <i>National Medical Director, Oncology Solutions Office of the Chief Medical Officer, Aetna</i>	
	CEUs: 0.050 The Growing Importance and Impact of Fair Market Value in Specialty Pharmacy	<i>Palazzo ABC</i>
	David Galardi, <i>Vice President, Worldwide Managing Director Apogenics</i>	
2:00 pm – 2:15 pm	Break	<i>Palazzo & Mediterranean Foyers</i>
2:15 pm – 2:45 pm	BREAKOUT SESSIONS <i>(two concurrent)</i>	
	CEUs: 0.050 Value-Based Contracting — The Future for Specialty Survival in the U.S.	<i>Palazzo E</i>
	Steve Clark, <i>Vice President, Optum Life Sciences</i> Brian Solow, <i>Chief Medical Officer, Optum Life Sciences</i>	
	CEUs: 0.050 Opposing Influences of Evidence and Market Forces in Pharmaceutical Pricing and Payer Net Cost	<i>Palazzo ABC</i>
	Larry Blandford, <i>Executive Vice President & Managing Partner Precision for Value</i> Steve Carter, <i>Vice President, Precision for Value</i>	
2:45 pm – 8:00 pm	Open Afternoon and Evening for Private Meetings <i>If you're not in a private meeting, be sure to spend some time in the hotel Lobby to catch up with old colleagues and make new business connections.</i>	
8:00 pm – 10:00 pm	Cocktail and Dessert Reception	<i>Lobby Bar</i>



Session Details & Notes





sPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

CPE INFORMATION

CPE Information



Changing Tomorrow, Together

At Astellas, we believe we can make a real impact on the future.

That's why we are fully committed to developing medicines that make a difference where they're needed most, in areas like oncology, urology, cardiology and transplant. It's also why we focus on bringing together a diverse group of people with a common goal: to help transform lives. Whether it's in the office, the laboratory or the community, **we're working together to change tomorrow.**



@AstellasUS

www.astellas.us

CPE Information



PCMA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). The 2016 sPCMA *Business Forum* agenda includes 16 CPE-eligible sessions. Because sessions are scheduled concurrently, individuals may obtain up to 4.5 total contact hours or 0.40 Continuing Education Units (CEUs) of education.

All sessions eligible for CPE credit are designated with *red notes* in the agenda.

Target Audience

All PCMA-offered CPE sessions are designed to be knowledge-based (K) activities for pharmacists (P). These sessions are designed to add to or enhance participants' knowledge of issues relevant to various pharmacists' career settings, including specialty pharmacy, and the business strategies that impact them.

PCMA-offered CPE sessions are designed to meet the educational needs of pharmacists from local, regional, and national specialty pharmacies, PBMs, employer-payer organizations, managed care and insurance organizations, drug manufacturers, distributors, and numerous other specialty pharmacy stakeholders and service companies. Educational sessions are designed for those new to the business of specialty pharmacy, as well as for more season veterans.

Obtaining Credit

As of January 1, 2013 a system called the CPE Monitor, a joint collaboration between ACPE and NABP, became mandatory for all CPE providers and pharmacists to submit and receive CPE credit. The CPE Monitor allows providers to submit attendee lists online. The system communicates this information to NABP, which then communicates it to state boards of pharmacy electronically, removing the need for pharmacists to submit individual statements of credit.

In order to receive credit for attending accredited CPE offerings, you must have an e-profile ID number (e-PID) provided by NABP. If you have not yet obtained your NABP e-PID, please do so at https://store.nabp.net/OA_HTML/xxnabpibeGblLogin.jsp?log=t. Questions about this system or your number should be directed to NABP customer service at 847.391.4406.

At the Conference: Be sure to write your name, birthdate, and NABP-e-PID on the sign-in sheet so that we may verify your attendance. Sign-in sheets will be placed on a designated table inside each CPE-eligible session room.

After the Conference: Be on the lookout for post-conference communications from PCMA. Depending on the session(s) you attend, it might be necessary for you to complete a learning assessment or evaluation before receiving credit.

PCMA will let you know when credit has been submitted electronically. Credit should appear in your NABP account within a week of being submitted.

State Requirements: Some states have specific CPE requirements. Be sure to check with your state Board of Pharmacy to determine if such requirements exist and to determine if these programs meet those requirements.



Disclaimers

- » PCMA plans all CPE-eligible sessions independent of commercial interests and PCMA does not accept grants to support any specific CPE programming.
- » Educational content should be presented with full disclosure and equitable balance and should not include anything which is promotional, commercially biased, or which appears to endorse a drug, device, or other commercial product or specific commercial service.
- » The opinions expressed by speakers are those of the individual presenters. They do not necessarily reflect the views of PCMA or its members.
- » CPE sessions may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product to review information of approved indications, contraindications, and warnings.



sPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

SPEAKERS

Speakers

REALIZING THE VALUE OF INNOVATION



Patients, Science, and Innovation are the foundation of everything we do. At Celgene, we believe in an unwavering commitment to medical innovation, from discovery to development. Our passion is relentless—and we are just getting started.



Speakers



Michael Anderson
Chief Pharmacy Officer
UnitedHealthcare Medicare & Retirement

Michael Anderson currently serves as Chief Pharmacy Officer for UnitedHealthcare Medicare & Retirement. In this role, Anderson leads development of formulary and clinical program strategy for the nation's largest private Medicare plans, serving over 8 million beneficiaries with approximately \$25 billion in annual drug expenditures.

Anderson has specialized in geriatrics throughout his career. Upon receiving his Doctor of Pharmacy degree from the University of Minnesota, he completed a residency in geriatric pharmacotherapy at the Minneapolis VA Medical Center — Geriatric Research, Education and Clinical Center.

Anderson joined UnitedHealth Group in 2002 and went on to help lead the Medicare Part D launch in 2006. He was subsequently promoted to his current role as Chief Pharmacy Officer.

Anderson is a veteran who served on active duty in the U.S. Air Force from 1988–1992, during Operation Desert Storm. He advises the Department of Defense on the development of the uniform formulary covering TRICARE beneficiaries, as a member of the Uniform Formulary Beneficiary Advisory Panel.



Steve Avey
Vice President, Specialty Pharmacy
MedImpact

Steve Avey received both his bachelor's degree and his Master of Science in Pharmacy Administration from the University of Utah. He began his pharmacy career in the retail sector and owned and operated Avey's Medical Village Pharmacy for nine years. His focus in his early career was on geriatrics in the long term care setting and psychiatry.

In the late 1990's Avey worked for Prospective Health Inc. and helped establish and run their Data Services division in Scottsdale, AZ. This company is known today as Relay Health. In 2000 after serving as Treasurer and President of the Academy of Managed Care Pharmacy (AMCP) he was hired as the Executive Director of their Foundation. For five years Avey set up education and research programs assisting P&T Committees across the country improving their assessment of new drug therapies and developed quality improvement measures in overall managed care practice.

In 2005 Avey left FMCP to become the Vice President Managed Care at Partners Rx Management in Scottsdale, AZ. That year, the Academy honored him by renaming their prestigious lifetime achievement award to the Steven G. Avey Award, recognizing his achievements in quality measurement programs and improving the drug assessment processes in the U.S.

Avey joined RegenceRx as a Vice President and worked as a part of senior management to assess the services, network rates and rebates to determine how RegenceRx could better serve their health plan. In January 2013 Avey was named Vice President, Specialty Pharmacy for MedImpact in San Diego, California. In this role, Avey sets the overall business strategy in the specialty arena and is developing a team to support MedImpact's clients as they forge into the new era of substantial specialty usage and spend.

In April, 2014 Avey received the designation of Fellow of the Academy of Managed Care Pharmacy. This is a prestigious designation that only a small number of managed care pharmacists have received.



Larry Blandford
Executive Vice President & Managing Partner
Precision for Value

Larry Blandford, PharmD, is the Executive Vice President and Managing Partner of Precision, specializing in Integrated Market Access, where he leads the strategic insights and market expertise capabilities. Prior to the acquisition of Hobart Group Holdings by Precision for Medicine in 2013, he held a similar position as Managing Partner of Hobart Innovations, the Strategic Services division of HGH. He has served numerous roles in the health care industry for more than 20 years, ranging from pharmacy benefit management and health information technology to market access consulting and pharmacy practice.

Prior to joining Hobart, Blandford held leadership roles in product development and sales and account services for 14 years at CVS Caremark. During his time there, he led initiatives in physician connectivity, as well as electronic prescribing programs, and he was responsible for developing and maintaining strategic relationships with key payer clients. In addition, Blandford's career includes roles in clinical PBM products, disease management initiatives, pharmacy and therapeutics committees, health information technology, and pharmacy practice in both hospital and retail settings.

Blandford is a participating member of several professional associations, including the Academy of Managed Care Pharmacy and the Kentucky Health Information Exchange Coordinating Council, where he represents pharmacy health IT interests and serves on the Business Development and Finance Committee.

He has authored and coauthored publications for managed care journals, including the *Journal of Managed Care Pharmacy* and the *American Journal of Health-System Pharmacy*.

Blandford received his Doctor of Pharmacy from the University of Kentucky and completed his managed care pharmacy residency training at Advance Paradigm, Inc., and the University of Maryland School of Pharmacy.



Stephen Carter
Vice President
Precision for Value

Stephen Carter is a Vice President at Precision Advisors, where he leads managed markets strategy team members, client engagements, and business development. Carter has more than 15 years of life sciences consulting experience across a wide variety of engagements. He has assisted top pharmaceutical, biotechnology, device, and nutritional clients with numerous product, portfolio, and corporate strategy issues.

Carter has expertise in pricing and market access, opportunity valuation, product launch, channel strategy, customer segmentation, contracting, and competitive simulation.

Carter is a contributing author to a variety of published articles and industry briefs. He has also presented at both national and international conferences and forums, on topics ranging from payer value proposition and pricing to the impact of health care reform. He is also a member of the Academy of Managed Care Pharmacy.

Carter received his Bachelor of Science degree in economics from Massachusetts Institute of Technology in Cambridge.



Steve Clark
Vice President
Optum Life Sciences

Steve Clark has 20 years of experience helping pharmaceutical and medical device companies in marketing, clinical, and reimbursement areas. He has worked with numerous early-stage technologies to assess reimbursement issues and develop strategies for assessment of market differentiation opportunities. The work has included stakeholder analysis for payers, clinicians, and health policy analysts, as well as horizon scanning assessments for market opportunity and comparative analysis.

Clark has helped Optum clients develop clinical strategies to obtain market differentiation for treatments and ultimately obtain positive coverage. He has supported clients in their development of clinical and cost outcomes to support the benefits of their products. And he has created successful pricing strategies.



Mary Dorholt
Senior Director & Specialty Clinical Practice Lead
Express Scripts

Mary Dorholt, PharmD, leads Express Scripts' specialty clinical strategy and protocol development. In this role, Dorholt and her team of clinical experts develop clinical guidelines for patient care and physician interaction for this complex and growing area of the pharmacy and medical benefit. This team also oversees development of clinical elements of the specialty care service portfolio for Express Scripts.

Dorholt is also responsible for driving organizational research on specialty medications and the Express Scripts experience. She has a 17-year history at Express Scripts and the former Medco organization. Prior to her current role, Dorholt was responsible for the provision of specialty strategic guidance to employer, government, and labor organizations. In this capacity, she was also responsible for marketplace oversight and internal and external communications related to specialty drug management.

Dorholt has extensive knowledge and experience in the development and implementation of specialty solutions, Medicare Part D strategies, and clinical payer support services. She has been a frequent speaker on specialty and Medicare topics during her tenure.

Dorholt received her Doctor of Pharmacy degree from the University of Minnesota College of Pharmacy in Minneapolis. She also holds bachelor's degrees in mathematics and biology.



Adam Fein
President
Pembroke Consulting

Adam Fein, PhD, is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the Chief Executive Officer of Pembroke's Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Fein is one of the country's foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on his insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving health care environment.

Fein's popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and he is quoted regularly in such national publications as *The Wall Street Journal*, *The New York Times*, *USA Today*, *Pharmaceutical Executive*, and many others. He serves on the Editorial Advisory Boards of *Pharmaceutical Commerce* and *Drug Benefit News*.

Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.

Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a BA, *summa cum laude*, from Brandeis University. He lives in Philadelphia with his wife and their two children.



Ronny Gal
Senior Analyst, Global Specialty Pharmaceuticals
Sanford Bernstein

Ronny Gal is the Senior Analyst at Sanford Bernstein covering Global Specialty Pharmaceuticals. Gal provides research and investment insight on specialty pharmaceutical stocks to institutional clients around the world.

Prior to joining Bernstein in 2004, Gal spearheaded Canon's business development in life sciences. He also spent six years with the Boston Consulting Group, advising clients in the pharmaceuticals and health care delivery industries.

Gal was awarded a PhD from the Massachusetts Institute of Technology and holds a BSc from Emory University. Gal has been named the No. 1 analyst in *Institutional Investor's* All-America Research Team survey for the past six years.



David Galardi
Vice President, Worldwide Managing Director
Apogenics

David Galardi, PharmD, is a straight-shooting health care consultant and co-founder of Apogenics, Inc. Always entertaining and known for bringing his breath of health care market experience to audiences seeking to learn more about the role of pharmaceuticals, biologics and personalized medicine play in society.

His diverse knowledge of managed care, provider operations, and product commercialization spans over 25 years. He has a deep knowledge of global market access challenges for pharmaceuticals, biologics, and diagnostics. He assists his clients with negotiations, helping them to determine fair market value and to build processes that are measurable through analytics.



Pat Gleason
Director, Health Outcomes
Prime Therapeutics

As Director of Health Outcomes at Prime Therapeutics, Patrick Gleason, PharmD, FCCP, BCPS, leads Prime's clinical health outcomes assessment team in the development and improvement of pharmacy benefit management programs. Through integrated medical and pharmacy claims data analysis Gleason assesses clinical program opportunity and post-implementation outcomes.

He has more than 40 peer-reviewed publications in medical and health policy journals such as the *Journal of Managed Care Pharmacy*, *Medical Care*, *Archives of Internal Medicine*, *Health Affairs* and *JAMA*.

Gleason is a past Chair of the JMCP Editorial Advisory Board and currently holds an Adjunct Professor of Pharmacy appointment at the University of Minnesota, College of Pharmacy. He is a Board Certified Pharmacotherapy Specialist (BCPS), as well as an elected Fellow of the American College of Clinical Pharmacy (FCCP).

He completed his Bachelor of Science and Pharmacy Doctorate degrees at the University of Minnesota. Gleason also completed an Ambulatory Care Pharmacy Practice Residency at the University of Pittsburgh Medical Center followed by a Fellowship in Outcomes Research through the University of Pittsburgh, School of Pharmacy.



Stephanie Hales
Partner
Sidley Austin LLP

Stephanie Hales is a Partner in the Healthcare and Government Strategies groups. She focuses her practice on health care regulatory, compliance, and legislative matters, including strategic counseling in connection with public policy proposals and implementation issues. Hales has experience in federal health care program coverage, coding, and reimbursement issues, government price reporting, administrative litigation, health care compliance programs, health information privacy and security, managed care matters, health care contracting, government agency and congressional investigations, and health care fraud and abuse.

Hales has advised numerous clients on a broad range of provisions in the 2010 health care reform legislation (the Affordable Care Act (ACA)) and related implementation issues including changes to the Medicare, Medicaid, and 340B programs, the annual fee on brand-name prescription drugs, the development of the ACA-created Exchanges and Essential Health Benefits package, implementation and enforcement of the ACA's nondiscrimination provisions, administrative simplification provisions and HIPAA amendments, increased transparency requirements under the Sunshine Act, and other reforms affecting government health care programs and the commercial insurance market. She has also served as adjunct faculty for a graduate-level health policy course, titled "The Future of American Health Care System: Health Policy and the Affordable Care Act," offered through the University of Pennsylvania Department of Medical Ethics & Health Policy.

Hales regularly counsels clients on health care legislative and regulatory developments and their impact, providing strategic advice, analysis, and advocacy targeted to company personnel as well as to courts and policymakers in Congress and at federal and state agencies.

Hales' clients have included pharmaceutical, biologics, and medical device manufacturers, durable medical equipment suppliers, patient advocate organizations, clinical laboratories and diagnostic test manufacturers, health care professional societies, health information technology companies, hospitals, and physician practices, among others. She also has represented a number of individuals and organizations on a pro bono basis in matters challenging Medicaid coverage denials, appealing disability benefits denials, advocating on health care public policy issues, and seeking relief in connection with criminal justice issues.



Mike Kolodziej
National Medical Director, Oncology Solutions
Office of the Chief Medical Officer
Aetna

Michael Kolodziej, MD, is the National Medical Director, Oncology Solutions in the Office of the Chief Medical Officer for Aetna.

Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia.

After completing training, Kolodziej joined the faculty at the University of Oklahoma School of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics Committee, on the Executive Committee from 2002–2011, and Chairman from 2004–2011.

Kolodziej served as Medical Director for Oncology Services for US Oncology from 2007–2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology.

Kolodziej has published several manuscripts and given several presentations on oncology care delivery and reimbursement reform, use of evidence based treatment to enhance value, and personalized medicine.

Since joining Aetna in January, 2013, Kolodziej has been active in Aetna's oncology delivery reform pilots, pharmacy policy, condition analysis, and genetics subcommittee.

He is a Fellow of the American College of Physicians, and he is a member of the board of the Personalized Medicine Coalition. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children.




Doug Long
Vice President, Industry Relations
IMS Health

Doug Long is Vice President of Industry Relations at IMS Health, the world's largest pharmaceutical information company. IMS Health offers services to the pharmaceutical industry in over 101 countries around the globe.

Long has been with IMS Health since 1989. His fundamental task is to help secure data for all existing and new databases supported by IMS Health, manage supplier, manufacturer, and association relationships, and to develop information for data partners. As direct consequence of his involvement in these areas, he has considerable experience with and a unique perspective on, the changing U.S. and global health care marketplace and pharmaceutical distribution.

Long is a frequent Industry speaker and recently received the distinguished Harold W. Pratt Award from NACDS, which recognizes individuals whose activities have contributed to the promotion, recognition, and improvement of the practice of pharmacy within the chain drug industry. He was previously honored with the 2004 HDMA NEXUS Award. The Nexus award is the industry's highest recognition award, honoring exceptional character, accomplishments, and leadership in the pharmaceutical distribution industry. He also received IMS's prestigious Summit award in 2003.

Prior to IMS Health, Long was at Nielsen Market Research for sixteen years in various sales and marketing capacities. A native of Illinois, he received a BA degree from DePauw University in Greencastle, Indiana, and an MBA in Management from Fairleigh Dickinson University in New Jersey.




Bill Martin

Vice President, Accredo Specialty Trade Relations Express Scripts

As Vice President, Accredo Specialty Trade Relations, Bill Martin leads a team that works closely with pharmaceutical and biotech clients to address strategic needs and to provide ongoing support through all phases of the product life cycle. This expertise includes pre and post launch planning, distribution, reimbursement, adherence, and high-touch support services.

Martin previously served as Vice President of Business Development and Strategy for Accredo and has more than 25 years of experience in the health care industry. Martin has held various positions of leadership including general management, marketing, medical education, sales, and product development. His key areas of interest include rare disease support strategies, distribution channel strategies, and the developing biosimilars marketplace.

Martin holds a bachelor's degree in communications and business from The University of Tennessee.



Mark Merritt

President & Chief Executive Officer PCMA

Mark Merritt is the President and Chief Executive Officer of PCMA, which represents the nation's PBMs. The PBM industry plays a pivotal role in American health care, administering prescription drug benefits for over 200 million Americans covered by Fortune 500 companies, health insurance plans, labor unions and Medicare Part D.

Before joining PCMA, Merritt played senior roles with America's Health Insurance Plans (AHIP), the Pharmaceutical Research and Manufacturers of America, and the presidential campaigns of Senators Bob Dole and Lamar Alexander.

Merritt also served as a Fellow at Harvard University's John F. Kennedy School of Government, where he lectured on the intersection of politics, public policy and the media. Merritt is known for innovative, campaign-style public relations strategies that reach beyond Washington to Wall Street, Main Street, even Hollywood.

In 2003, Merritt took the helm of PCMA and quickly bolstered its stature and clout. He is routinely ranked among the nation's most effective association executives and is a member of the U.S. Chamber of Commerce's elite "Committee of 100." Recognizing his tireless efforts promoting affordable medicines, the Generic Pharmaceutical Association selected Merritt for its 2011 "Outstanding Contribution" award.

Merritt serves on the Editorial Advisory Board for *Drug Benefit News* and the Board of The Public Affairs Council, which represents communications professionals worldwide.

He holds a BA and MA from Georgetown University. He and his wife Jayne have four children.



Jerry Miller
Healthcare Industry Consultant

Jerry Miller, PharmD, is President of J. Miller Consulting, and provides consultative services to pharmaceutical or biotech companies and other health care-related firms. He is a former Director of Research with Health Strategies Group, specializing in the PBM and managed markets industry segments. In his twelve years with this firm, he gained recognition as an industry expert by pharmaceutical manufacturer clients and PBM industry senior leaders.

Miller has a broad background and experience in multiple areas of the profession of pharmacy including hospital, retail, managed care, Medicaid, and PBMs. His experience includes six years as a member of the pharmacy administrative staff at Cedars-Sinai Medical Center where he supervised the department's purchasing, emergency, and operating room services, and the Pharmacy & Therapeutics Committee. Joining American Stores in 1988, Miller worked as a Sav-on pharmacy manager, then as the corporate liaison to Cigna of California and Molina Healthcare. He next joined RxAmerica, now owned by CVS Caremark, serving as Director of Clinical Services for over five years.

Miller received his Doctor of Pharmacy degree from the University of Southern California in Los Angeles.



Everett Neville
Senior Vice President, Supply Chain
Express Scripts

As Senior Vice President of Supply Chain for Express Scripts, Everett Neville is responsible for all aspects of supply chain. He has a unique understanding of the pricing and reimbursement landscape and is a champion for our clients' needs in his management of our relationships with pharmaceutical manufacturers. Neville reports to David Norton.

A pharmacist by training, Neville joined Express Scripts 16 years ago and in addition to his leadership roles in Supply Chain, he also held a leadership role in their Health Plan division.

Neville holds a Bachelor of Science degree in pharmacy from the University of North Carolina and an MBA from the University of Missouri - St. Louis.



Lee Newcomer

Senior Vice President, Oncology, Genetics and Women's Health **UnitedHealthcare**

Lee Newcomer, MD, MHA, is a Senior Vice President at UnitedHealthcare with strategic responsibility for Oncology, Genetics and Women's Health.

Newcomer is a board certified medical oncologist. He practiced medical oncology for nine years in Tulsa, Oklahoma, and Minneapolis (Park Nicollet Clinic). He is the former Chairman of Park Nicollet Health Services (now HealthPartners), an integrated system of physicians and hospitals in the Minneapolis and St. Paul metropolitan area. The group is nationally recognized for its leadership in quality, safety, and cost-effectiveness.

Newcomer began his management career as a Medical Director for CIGNA Health Care of Kansas City in 1990. From 1991 to 2000, Newcomer was the Chief Medical Officer at UnitedHealthcare where his work emphasized the development of performance measures and incentives to improve clinical care. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. He returned to UnitedHealthcare in 2006 to focus on combining clinical, financial, and administrative incentives for improved and affordable cancer care.

Newcomer earned a BA degree from Nebraska Wesleyan University, an MD degree from the University of Nebraska College of Medicine, and a Masters of Health Administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine at the University of Nebraska Medical Center and a fellowship in medical oncology at the Yale University School of Medicine.



Betty Nguyen

Journalist & Anchor **NBC News & MSNBC**

Betty Nguyen is an award-winning journalist and host whose work has taken her across the globe. She has spent her entire career covering some of the most important issues of our time. As an anchor for NBC News and MSNBC and correspondent for the Today Show, Nguyen has most recently covered the Ebola outbreak, the Boston Marathon bombings, the election of Pope Francis, and the birth of Prince George of Cambridge.

Before her move to NBC, Nguyen was news anchor for CBS This Morning Saturday. She was also a correspondent for The Early Show, and anchor of the CBS Morning News. At Morning News, she covered the 2012 Presidential election, the 2011 earthquake in Japan, the death of Osama Bin Laden, the Royal wedding, and the Gulf oil spill. In addition, Nguyen served as special correspondent for *Entertainment Tonight*. Prior to working at CBS, she anchored the weekend edition of *CNN Newsroom*. Before joining CNN, Nguyen was an anchor for KTVT in Dallas and a freelance correspondent for E! Entertainment Television.

Nguyen is the co-founder of Help the Hungry, a global non-profit organization that aims to alleviate hunger, address poverty, and provide a lifeline to those in need.



Sam Nussbaum

***Former Executive Vice President, Clinical Health Policy
& Chief Medical Officer
Anthem***

From 2000 until 2016, Dr. Samuel Nussbaum, MD, served as Executive Vice President, Clinical Health Policy and Chief Medical Officer for Anthem. In that role, he was the key spokesperson and policy advocate and oversaw clinical strategy and corporate medical and pharmacy policy. Nussbaum was responsible for HealthCore, Anthem's clinical outcomes research subsidiary. He helped construct the model that has evolved into the current FDA Safety Sentinel System. In collaboration with other medical leaders, he helped design and promote patient-centered medical homes and assessed their impact on the quality and cost effectiveness of care.

During his tenure at Anthem, Nussbaum was responsible for more than \$100B in health care expenditures through business units focused on care and disease management, health improvement, and provider network contracting. He was instrumental in developing contracting approaches that link hospital reimbursement to quality, safety, and clinical performance. Under his leadership, HealthCore built partnerships with federal agencies and academic institutions to advance drug safety, comparative effectiveness, and outcomes research.

Nussbaum currently serves on the Board of Directors of the OASIS Institute, NEHI, BioCrossroads, an Indiana-based public-private collaboration that advances and invests in the life sciences, and America's Agenda. He is a member of the Scientific Advisory Board of Medidata, a publicly traded clinical technology company serving life sciences clients, and the Healthcare Advisory Board of KPMG. He serves as Chair of the Centers for Education & Research on Therapeutics (CERTs) Steering Committee, a cooperative agreement between AHRQ and the FDA; he is a member the HHS Health Care Payment Learning and Action Network (LAN) Guiding Committee; and he participates in Institute of Medicine activities, including serving on the Roundtable on Value & Science-Driven Health Care.

Nussbaum has served as President of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, and Chair of America's Health Insurance Plans' (AHIP) Chief Medical Officer Leadership Council. He has served on the boards of AHIP, the National Quality Forum, and on the Secretary of Health and Human Services' Advisory Committee on Genetics, Health, and Society. Nussbaum received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives and *Modern Physician* magazine and has been recognized by *Modern Healthcare* as one of the "50 Most Influential Physician Executives in Healthcare."

Prior to joining Anthem, Nussbaum served as Executive Vice President, Medical Affairs and System Integration of BJC Health Care, where he led integrated clinical services and served as President of its medical group and Chairman of its commercial (HealthPartners of the Midwest) and Medicaid (CarePartners) health plans. Under his leadership, BJC acquired the medical group aligned with Coventry Health Care's Group Health Plan, and created a continuum of care which enabled BJC to enter into fully-capitated contracts with insurers. Under his leadership, BJC received the National Quality Award.

Nussbaum had a 20 year academic career at Massachusetts General Hospital and Harvard Medical School where he led the Clinical Endocrine Group Practice. As a professor at Harvard Medical School, his basic and clinical research on hormones and factors that control calcium metabolism and bone growth led to clinical trials of treatments for osteoporosis and skeletal complications of cancer; and FDA approved drugs that have important roles in clinical care. He also developed new technologies and approaches to measure hormones in blood and helped commercialize these laboratory tests.

Nussbaum received his undergraduate degree from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology and metabolism at Harvard Medical School and Massachusetts General Hospital. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.



Steve Pearson
President
Institute for Clinical and Economic Review

Steven Pearson, MD, MSc, FRCP, is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations and moves that evidence into action to improve patient care and control costs. ICER's programs include the California Technology Assessment Forum and the New England Comparative Effectiveness Public Advisory Council, both of which seek to support all health care decision makers in the interpretation and application of evidence on clinical effectiveness and value.

Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School, and he also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. He attended UCSF School of Medicine, completed his residency in internal medicine at Brigham and Women's Hospital in Boston, and he obtained a Master of Science degree in Health Policy and Management at the Harvard School of Public Health. An internist, health services researcher, and ethicist, Pearson has served in many advisory and leadership roles in academia and government.

In 2004 Pearson was awarded an Atlantic Fellowship from the British Government and chose to serve as Senior Fellow at the National Institute for Health and Clinical Excellence. Returning to the United States in 2005 he was asked to serve for one year as Special Advisor, Technology and Coverage Policy, within the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services. He has also served as Senior Fellow at America's Health Insurance Plans, as the Vice Chair of the Medicare Evidence Development and Coverage Advisory Committee from 2007–2009, and as a Member of the Board of Directors of Health Technology Assessment International from 2010–2013.

Today, Pearson continues to be active in various roles related to comparative effectiveness research and policy, including the AcademyHealth Methods Council, and the National Institutes of Health Comparative Effectiveness Research Steering Committee. Pearson's ongoing academic work combines efforts in comparative effectiveness research, health policy, and bioethics. His published work includes numerous articles and commentaries on the role of evidence in the health care system, and the book *No Margin, No Mission: Health Care Organizations and the Quest for Ethical Excellence*, published by Oxford University Press.



Bill Roth
Founding Partner
Blue Fin Group

Bill Roth is serial entrepreneur and a tenured corporate executive. As Founding Partner of Blue Fin Group, a management consultancy for the pharmaceutical industry, Roth started the company in 2001 and has grown the organization to service most manufacturers and a wide array of channels and service providers. He is considered an innovator and an expert in connecting health care products to patient populations. Roth has consistently forecasted future events in the industry, and he has led his clients and companies to successful outcomes for more than 25 years.

Roth has been quoted in dozens of industry publications. He is repeatedly cited by market researchers, analysts, and industry leaders for his accurate predictions, and he speaks frequently at industry events and seminars on the subject of commercialization and related issues. Roth's unique breadth of experience and knowledge from working with all models in the health care industry provides great context when working to solve challenging business puzzles in our industry.

Roth was featured as the cover story of Pharmaceutical Commerce in January 2016 and was featured in *Entrepreneur Magazine* in 2001. He is also a 2008 recipient of *PharmaVOICE magazine's* "Top 100 most-inspiring people in Life Sciences" and was named a 2009 "People to Watch" by *PM360 Magazine*.



Jason Rucker
Director, Trade Research
Zitter Health Insights

Jason Rucker, Director of Trade Research at Zitter Health Insights, has been working within the patient reimbursement and pharmacy industry for more than seven years. During this time, he has spent time designing and running patient reimbursement programs, product development, conducting trade relations, and most recently conducting consumer market research. In this later capacity, Rucker has gained a deeper understanding of the drivers that influence key stakeholders and the role they play during the patient journey.



Brian Solow
Chief Medical Officer
Optum Life Sciences

Brian Solow, MD, FAAFP, currently serves as the Chief Medical Officer for Optum Life Sciences, a segment of Optum and UnitedHealth Group. Optum Life Sciences helps pharmaceutical, biotechnology and medical device companies successfully address product development and commercialization challenges by delivering a full range of integrated solutions in the areas of strategic insight, value assessment, evidence development, alignment to commercial needs, and launch support. Prior to his current position, Solow served as the Chief Medical Officer for OptumRx which provides innovative PBM services and products to employer groups, union trusts, commercial, Medicare and other governmental health plans. Solow's primary responsibility there was the coordination of clinical activities related to the development, enhancement and implementation of clinical programs supporting formulary management for OptumRx clients.

Prior to joining the clinical team at Optum, Solow was an active member of a physician-owned medical group, maintaining a full-time practice while simultaneously holding various management roles within the group. He has served as a member of national pharmacy and therapeutics committees for leading managed care organizations and pharmacy benefit management firms. Solow is a well-known national and international speaker on a variety of topics relating to pharmacy management.

Solow holds an active appointment as clinical professor at the University of California, San Francisco, School of Pharmacy, and an appointment at the University Of Southern California School Of Pharmacy. He received the Family Medicine department award from the University of California, Irvine School of Medicine for distinguished practice and teaching.

Solow is a fellow of the American Academy of Family Physicians, a member of the U.S. Pharmacopeia Medicare Model Guideline Expert Panel advisory committee, as well as serving on FDA advisory panels. He is also active in ISPOR-serving as the U.S. representative for the Health Technology Assessment Council. The Orange County Medical Association has recognized him several times as a Physician of Excellence.



Thom Stambaugh
Vice President
Cigna Specialty Pharmacy Services

Thom Stambaugh, RPh, MBA, is Vice President of Cigna Specialty Pharmacy Services and leads the design and execution of the specialty pharmacy strategy to create solutions to improve the health, affordability, and human performance for the 3% of Cigna customers on specialty pharmaceuticals generating 26% of total medical costs. Thom is responsible for Cigna's specialty pharmacies that serve over 100,000 customers using over \$2B in specialty pharmaceuticals. He is the executive sponsor for several of Cigna Pharmacy Management's largest clients and represents Cigna in a variety of client and industry activities.

Prior to joining Cigna, Stambaugh was Director of Clinical Programs at Healthsource, where he designed and developed drug utilization programs for asthma, gastrointestinal, and narcotic medication management. As Manager of Clinical Pharmacy Consulting, while at Value Rx, he was responsible for implementing formulary and disease management programs for employer groups and health plans.

Stambaugh has published and been quoted in several industry publications related to evidence-based benefits, specialty pharmacy, outcome-based pharmaceutical manufacturer contracting and in support of the company's launch of Return on Health. Return on Health (ROH) elevates the concept of ROI — helping customers realize improved outcomes and lower costs through the synergy of clinical programs, plan design, financial management, and service across pharmacy, medical and behavioral plan components.

Stambaugh received a Bachelor of Pharmacy from Ohio Northern University and an MBA from the Owen Graduate School of Management at Vanderbilt University. He has also completed executive leadership programs through University of Southern California and University of Virginia's Darden School.



Debbie Stern
Senior Vice President, Strategy and Business Development, Medical Oncology and Specialty Pharmacy
eviCore healthcare

Debbie Stern, RPh, is Senior Vice President of Medical Oncology and Specialty Drugs at eviCore, where she is responsible for developing and executing new business and program strategies that focus on the incorporation of evidence-based guidelines in oncology and specialty pharmaceutical management with payers.

Stern is a nationally recognized expert on the integration of biotechnology and specialty pharmaceuticals into the payer marketplace. She regularly serves as a guest speaker for PCMA, AMCP, NASP, AIS, and Armada. Stern initiated the concept of the *EMD Serono Specialty Digest* in 2004 and has been its author and editor for the past eleven editions.

Stern currently serves on the Editorial Advisory Board of *AIS Specialty Pharmacy News* (Atlantic Information Services).

Previously, Stern served as Vice President and President of Rxperts, a managed care consulting firm dedicated to helping clients better understand the dynamics and market forces affecting managed pharmaceutical benefits. For more than 15 years, Stern has consulted in the areas of pharmaceutical and specialty pharmacy marketing, clinical program development, market assessment, strategy development, and strategy execution.

Prior to Rxperts, Stern was a senior level director at two national PBMs. She spent five years in the pharmaceutical industry and ten years in retail pharmacy. She has a BS in pharmacy from the University of

Cincinnati and is actively involved in the Academy of Managed Care Pharmacy where she previously served on the Board of Directors and chaired the Program Planning Committee. Debbie is a guest lecturer to the USC School of Pharmacy, UC Irvine MBA program, and Western School of Pharmacy.



Tim Wentworth
President
Express Scripts

Tim Wentworth, President and upcoming Chief Executive Officer of Express Scripts, has overall responsibility for all aspects of Express Scripts, including the PBM business, the home delivery pharmacy, the Accredo specialty pharmacy, and the company's other subsidiaries. He is responsible for ensuring Express Scripts delivers on its mission to make the use of prescription drugs safer and more affordable.

In his role, Wentworth also directly oversees information technology, marketing, operations, research and new solutions, sales and account management, and supply chain management.

Wentworth joined Express Scripts in 2012 as Senior Vice President and President, Sales and Account Management. He was promoted to President of the company in 2014, elected to the Board of Directors in January 2015, and will become CEO in May 2016.

Prior to joining the company, he led the employer and key accounts organizations at Medco Health Solutions for nearly 14 years. In 2006, Wentworth took a two-year break from his role in account management to serve as President and CEO of Accredo specialty pharmacy, leading the rapid and successful integration of Accredo into the broader Medco organization.

Before Medco, Wentworth spent five years at Mary Kay, Inc., where he served initially as Senior Vice President of Human Resources and subsequently as President, International. He also spent nine years in human resources management at Pepsi Co.

A well-respected leader in his field, Wentworth has been a featured speaker at Harvard University, the Health Evolution Summit, the American Management Association, and the Best 100 Companies Symposium, among other events. He is a Trustee of the University of Rochester (NY), serving on the Health Strategy and Personnel Committees.

Wentworth received his associate's degree from Monroe Community College; and a bachelor's of science degree in Industrial and Labor Relations from Cornell University.



Farrah Wong
Manager, Pipeline and Drug Surveillance
OptumRx

Farrah Wong, PharmD, is Manager of Pipeline and Drug Surveillance at OptumRx, one of the largest PBMs in the United States. Her primary responsibilities include overseeing drug pipeline, forecasting, and pharmacovigilance programs. These initiatives drive the development and implementation of effective strategies that focus on clinically sound and affordability measures.

Dr. Wong has 10 years of experience as a pharmacist in the managed care and clinical setting. She earned her PharmD degree from the University of Southern California and BS from the University of California, Los Angeles. She is an appointed faculty at the University of California, San Francisco School of Pharmacy, in conjunction with the OptumRx pharmacy residency program.



Martin Zagari
Vice President, Global Health Economics
Amgen

Martin Zagari, MD, is Vice President of Global Health Economics at Amgen. In this role, he directs the planning, execution, and scientific dissemination of worldwide economic and value evidence for Amgen's entire product portfolio from early stage molecules to marketed products. Zagari joined Amgen in May of 2005.

Prior to Amgen, between 1997 and 2005, Zagari held various positions at Johnson & Johnson in health economics, medical affairs, and strategic marketing. These positions included Executive Director in J&J Corporate Strategic Marketing for the erythropoietic agents, Medical Director for erythropoietic treatments in oncology at Ortho Biotech, and Director positions in health economics.

Between 1994 and 1997, Zagari worked in health economics and outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco.

Zagari received his MD from Stanford University, an MBA from Rutgers University, and BS in biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology.



Michael Zeglinski
Senior Vice President, Specialty Pharmacy
OptumRx

Michael Zeglinski, RPh, serves as Senior Vice President, Specialty Pharmacy, at OptumRx, the nation's third-largest PBM, and part of Optum, a leading information and technology-enabled health services business. The parent company, UnitedHealth Group, is a diversified health and well-being company which provides services to more than 85 million people worldwide and includes UnitedHealthcare, the nation's leading health care provider.

Bringing more than 25 years of experience in the pharmacy distribution and specialty pharmaceutical business, including home infusion therapies, Zeglinski leads the BriovaRx division, OptumRx's Specialty Pharmacy. BriovaRx is a full-service, innovative, patient-centric specialty pharmacy that services a diverse customer base, from patients and providers to payers and pharmaceutical manufacturers. Zeglinski is responsible for leading the division's strategy, sales efforts, product development, clinical and nursing programs, analytics/outcomes, and operations of 15 specialty pharmacies nationwide.

Prior to joining Catamaran in 2012 as the Vice President of Pharmacy Operations, Zeglinski held roles at several other specialty pharmacy organizations, including Quantum Health Resources, Olsten/Gentiva Health Services, Accredo Therapeutics and CVS Caremark. He has developed and implemented numerous pharmacy operating systems and disease-specific care management programs, which focus on increasing patients' specialty pharmaceutical adherence rates, documenting cost saving interventions and improving quality of life for patients/members. He is also Green Belt certified in Lean Six Sigma processes focusing on the health care industry.

Zeglinski holds a bachelor's degree in pharmacy from Duquesne University in Pittsburgh, PA, and pursued his Masters of Fine Arts in music from Carnegie Mellon University. He is a member of the Academy of Managed Care Pharmacy and the American Pharmacists Association and is currently licensed as a pharmacist in 13 states.



sPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2016

Marketplace

MARKETPLACE



Caring deeply about those around us

We know that living with multiple sclerosis (MS) can present some pretty large challenges. At Biogen™, we are committed to patients through ongoing research and support services to help meet unmet needs in the management of MS.

Visit Biogen.com, or call 1 800 456 2255.

Marketplace Directory

If you would like to connect or schedule an on-site meeting with any of the below conference sponsors, please use our directory to identify the appropriate contact.

AbbVie

Chris Compisi
General Manager, National Accounts
 christopher.compisi@abbvie.com

Allergan

Carter Dutch
Vice President, Corporate Accounts
 carter.dutch@actavis.com

Brian Ellis
Senior Director, Corporate Accounts
 brian.ellis@actavis.com

Astellas

James Miteff
Senior Director, Corporate and Government Accounts
 james.miteff@astellas.com

AstraZeneca

Tony Calucchia
Senior Director
 anthony.calucchia@astrazenecs.com

Baxalta

Todd Michael
Director, Marketing, Business Alliances
 todd.michael@baxalta.com

Bayer

Andy Beachley
Director, Specialty Pharmacy
 andrew.beachley@bayer.com

Ryan Munafo
*Director, Health Plans and PBMs
 Corporate and Government Customers*
 ryan.munafo@bayer.com

Biogen

John Newman
Senior Director, Payer and Channel Marketing
 jay.newman@biogen.com

Boehringer Ingelheim

Heather Montanaro
Project Manager, Managed Markets Marketing
 heather.montanaro@boehringer-ingelheim.com

Celgene

Rich Debone
Senior National Account Manager
 rdebone@celgene.com

Jeff Wunderlich
National Account Manager
 jwunderlich@celgene.com

CoverMyMeds

Kelly Gervolino
Director of Sales, Pharma
 kgervolino@covermymeds.com

Sam Rajan
Principle & Co-Founder
 srajan@covermymeds.com

EMD Serono, Inc.

Janice Pringle
Executive Administrative Assistant
 janice.pringle@emdserono.com

Genentech

Meaghen English
Operations and Communications Manager
 english.meaghen@gene.com

Genzyme

Edcardo Odom
Senior Manager
 edcardo.odom@genzyme.com

Gilead

Jim Ziegler
Senior Director, Market Access
 jim.ziegler@gilead.com

Johnson & Johnson

William Johnson
National Account Director
 wjohnso2@its.jnj.com

Lilly USA, LLC

John H. Poulin
Director, Professional Relations
jhpoulin@lilly.com

Mallinckrodt

Vanessa Harris, RN
Senior Director, Market Access, East
vanessa.harris@mallinckrodt.com

Mike Sweeting
Senior Director, Market Access, West
mike.sweeting@mallinckrodt.com

Medivation

Shirley Bachman
Director, Account Management
shirley.bachman@medivation.com

Mylan

Becky Gamble
Vice President, Managed Markets
becky.gamble@mylan.com

Novo Nordisk

Dianne Hanlon
Senior Administrator
dihn@novonordisk.com

Otsuka

Melissa M. Masterson
National Director, Market Access
melissa.masterson@otsuka-us.com

Pfizer

Michael Nuttall
Senior Director
michael.nuttall@pfizer.com

Regeneron

Laura Randa
Director, Payer Engagement
laura.randa@regeneron.com

Sandoz

Dan Spears
*Associate Director, National Accounts
U.S. Managed Markets*
daniel.spears@sandoz.com

Sanofi

Jeffrey Mehl
*Senior Director, Payer Engagement and
Communications*
jeffrey.mehl@sanofi.com

Sunovion

Janet Surovcik
Senior Corporate Account Director
janet.surovcik@sunovion.com

Takeda

Bill Richardson
*Senior National Director, National and
Specialty Accounts*
bill.richardson@takeda.com

Teva

George Keefe
Vice President, U.S. Market Access
george.keefe@tevapharm.com

UCB

Dede Conover
*National Account Executive, Market Access
Operations*
dede.conover@ucb.com

Valeant


Sandy Loreaux
Vice President, Market Access
sandra.loreaux@valeant.com

Vertex

Kelly Prescott
Director, Payer Strategy and Marketing
kelly_prescott@vrtx.com

XenoPort

Monica Mazziotti
Executive Director, Market Access
monica.mazziotti@xenoport.com



abbvie

**OUR HEART IS
ALWAYS IN OUR
WORK BECAUSE
OUR PATIENTS
ARE ALWAYS
ON OUR MIND.**

AbbVie addresses serious diseases with the innovative, entrepreneurial resources of a global pharmaceutical company. Our passion to develop and deliver new treatments that improve health and healthcare drives our science. Because every life is remarkable, our impact upon each must be equally so.

abbvie.com

Meet the **Bold** new **Allergan**

We are a bold new healthcare company. We are one team of dedicated employees, carving new paths, taking bold, decisive actions to deliver results and better outcomes for patients and providers.

We work in a fast-changing industry. We thrive in this environment. We know that change = opportunity, and we are prepared to lead change. We bring new ideas to render a powerful impact on human lives around the world.

We love what we do. We have momentum. This is our moment.

We are the new Allergan.

www.Allergan.com



What science can do



Advancing Quality of Patient Care

At AstraZeneca, we know improving the lives of patients requires engagement across all of healthcare, and we are committed to pursuing innovative collaborations that advance quality of care, improve patient outcomes and deliver value to the healthcare system.

We also work to support meaningful access to our medicines and actively engage patients in their own care along with their healthcare professionals to help slow progression of disease, reduce readmissions, and decrease complications.


To learn more about how AstraZeneca is pushing the boundaries of science to deliver life-changing medicines, transforming serious diseases like cancer, heart disease, diabetes, and asthma, visit astrazeneca-us.com.

Oncology combination therapies

AstraZeneca is investigating combinations of biologic and small-molecule therapies for the treatment of cancer. These combinations target the tumor directly and some help boost the body's own immune system to potentially induce cell death.



Nurturing innovative ideas today for more health tomorrow.




Boehringer Ingelheim ranks among the world's 15 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

For more than 125 years, Boehringer Ingelheim has been committed to the research and development of innovative medicines that help make more health for patients and their families.

Visit us online at
us.boehringer-ingelheim.com



covermymeds®



The Nation's Largest Electronic Prior Authorization Network Integrated in the Clinical Workflow



360+
INTEGRATED EHRs



72%
OF U.S. PRESCRIPTION
VOLUME



500,000+
PRESCRIBERS
45,000+ PHARMACIES



80%
OF PHARMACY
MARKET

Learn more: covermymeds.com • 1-866-452-5017



Helping people is what makes science

human

If you care to explore our commitment to patients, visit emdserono.com.



**EMD
SERONO**

The biopharma
business of Merck KGaA,
Darmstadt, Germany.



IT'S THE
EVERYDAY
THAT CHANGES
EVERYTHING

We believe in more than the big breakthroughs. And more than the next big thing.

We believe in the day-in day-out work of making science happen. And the millions of little victories — and failures — in between the breakthroughs. Because to us, it's the daily effort of everyday people that changes the future. So we don't stop. We keep working. Every day.

Genentech
A Member of the Roche Group

Jacki, patient

Every challenge creates opportunity
Every relationship brings responsibility

Johnson & Johnson

HEALTH CARE SYSTEMS INC.

Providing services for Janssen Pharmaceutical Companies of Johnson & Johnson



Every patient is
our *inspiration*



*Hong Hu, Research Advisor,
Lilly Research Laboratories*

It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/about.

2015 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.



More than **18,000**
employees in the United States

A comprehensive offering of
medicines, vaccines and
innovative services all over
the world

More than **120** locations
across North America

© Blue Images/Corbis - 00yoo/getty images

SANOFI FOCUSED ON PATIENTS' NEEDS

Over the years, Sanofi has evolved to meet the new challenges of healthcare worldwide. Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat them, and provide support to them. Through our diversified portfolio of medicines, vaccines and innovative therapeutic solutions, we strive to protect the health and meet the needs of the world's 7 billion people.

Sanofi is proud to support PCMA, the Pharmaceutical Care Management Association

US.COR.14.06.005



For more information: www.sanofi.com - www.sanofi.us

www.facebook.com/sanofiUS  www.twitter.com/sanofiUS  www.pinterest.com/sanofiUS **SPEAKING OF SANOFI**  blog.sanofi.us


Sunovion supports PCMA in its mission to promote industry relations and thought leadership throughout the pharmaceutical supply chain



A proud sponsor of the 2016 sPCMA Business Forum, Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Our spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives.

Visit us at www.sunovion.com and connect with us on [Twitter @Sunovion](#) and [LinkedIn](#).





MANAGED MARKETS

An eye care company that puts
your plan's needs in view.

Visionary.

At Alcon, we know that you need a partner who understands your organization and its members. Our expertise in both vision care and managed markets allows us to deliver exactly what you need—leading pharmaceuticals and vision care products.

Contact your Account Manager today. Together we can make sure you and your members see things clearly.

Alcon[®]
a Novartis company

©2015 Novartis 2/15 MGC15003JAD



 **SANDOZ**
Biopharmaceuticals

***Dedicated to helping you
provide affordable, high-quality
Biopharmaceuticals***

Call your Account Manager for more information,
or reach us at http://sandoz.com/tools/contact_us/
and we will have your Account Manager contact you



DRIVEN BY CUSTOMER NEEDS? | AT BAYER YOU'RE EXPECTED TO BE.

At Bayer we always start by listening – because our customers are at the heart of everything we do. The needs of our customers and the challenges facing society inspire us to develop ideas that improve people's lives.

As part of the Bayer team, each of us needs to thoroughly understand and support our customers in order to deliver products and solutions that matter – now and in the future.



Science For A Better Life


Passion to innovate | Power to change



FOCUSED ON DEVELOPING SPECIALTY TREATMENTS for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofigenzyme.com

SANOFI GENZYME 



MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB. BUT THEY BEGIN IN THE HEART.

For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we're doing it, with a long-standing commitment to research and development. We're just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we'll meet that challenge. With all our heart.



For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0006 01/13



We all share
one wish.
To go where
our dreams
take us.

At Mylan, we're
committed to helping
people live their dreams
by providing access to
quality healthcare for the
world's 7 billion people,
one person at a time.

Better health
for a **better world**™

Mylan.com

 **Mylan**
Seeing
is believing®

Better Health, Brighter Future



Working in Partnership with You

We're driven to improve people's lives.

Takeda strives toward better health for people worldwide through leading innovation in medicine. At Takeda, we make a commitment to make a difference.

Takeda Pharmaceuticals U.S.A., Inc.

www.takeda.us
USD/TAK/15/0042c

Baxalta

Your life. Our inspiration.

Baxalta Incorporated is a global biopharmaceutical leader developing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Baxalta is driven by passion to make a meaningful impact for patients. At Baxalta, your life is our inspiration — that's the promise of the Baxalta spark.

Baxalta.com



Advancing Therapeutics, Improving Lives.

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

For more information, please visit www.gilead.com.
© 2015 Gilead Sciences, Inc.




SEEING **COMPLEXITY** IN A NEW LIGHT.

For nearly 150 years, Mallinckrodt has made complex scientific problems manageable, developing valuable diagnostic tools and treatments for patients who need them.

We view challenges as opportunities.
See how at Mallinckrodt.com



Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.
© 2016 Mallinckrodt. June 2015



Proud to be your partner

Committed to partnerships, Medivation is honored to support the Specialty Pharmaceutical Care Management Association.

Through our extensive research network and the expertise of our world-class core team, we identify pathways to the most rapid, efficient, and effective development of novel therapies for patients with serious diseases.

To ensure access to our innovative medical solutions, we partner with a network of specialty pharmacies to identify patients' financial assistance needs, help reduce access barriers, and provide educational resources with every prescription delivery.

Learn more about our commitment to partnerships at medivation.com.



©2015 Medivation, Inc. All rights reserved. Printed in USA. BCM-MDV-US-0004 12/15



People creating new products for better health worldwide

The name “Otsuka” translates to “major milestone.”

And indeed, for over 85 years,

Otsuka's people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We've funded new research, supported new clinical trials, and pursued the development of new medications - an unfaltering commitment of energy and resources with one goal in mind - to create new products for better health worldwide. mind

1.800.562.3974

www.otsuka-us.com


Otsuka America Pharmaceutical, Inc.

Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Maryland Medicinal Laboratories, Inc.

© 2016 Otsuka America Pharmaceutical, Inc.

January 2016 01US16EUC001



Decisions that fit Programs that matter Solutions that count

A privately held pharmaceutical company founded by physicians, Purdue is dedicated to meeting the needs of our Managed Care partners by developing programs that improve both patient care and patient safety:

- **PartnersAgainstPain.com** offers people living with pain, as well as their friends and families, comprehensive and clear information on a wide variety of pain issues
- **RxSafetyMatters.org** is an online resource for healthcare professionals, law enforcement, and community organizations to help combat the illegal diversion and abuse of prescription medications

Proud sponsors of



THE PARTNERSHIP™
AT DRUGFREE.ORG



PurduePharma.com

©2012 Purdue Pharma L.P., Stamford, CT 06901-3431 B8248-HP 3/12



Anita completed her first of many triathlons at age 57.

Pfizer developed **Get Old** to challenge us to rethink aging and take a more active role in our health.

At Pfizer, we make medicines and vaccines that extend and improve lives, yet we know that medicines alone cannot give you a healthy life.

It's time to challenge how we think about aging and look forward to what's yet to come. To learn more, visit GetOld.com.



**Science drives our business,
and passion drives our science.**

At Regeneron, we bring innovative thinking to the discovery, development and commercialization of treatments that help improve the lives of patients in need.

REGENERON
science to medicine®



Valeant Pharmaceuticals International, Inc. is committed to innovation and to introducing products that make a meaningful difference in patient's lives.

 **VALEANT**
Pharmaceuticals International, Inc.

WWW.VALEANT.COM



THE SCIENCE *of* POSSIBILITY

Vertex creates new possibilities in medicine to cure diseases and improve people's lives.

We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

www.vrtx.com

© 2015 Vertex Pharmaceuticals Incorporated 12/15



TRANSPORTING THE
POWER OF PHARMACEUTICALS

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinson's disease and relapsing-remitting multiple sclerosis.


To learn more, visit www.XenoPort.com

©2015 XenoPort, Inc. All rights reserved.

Introducing sPCMA.org


PCMA's New Platform for Specialty Pharmacy Insights and Thought Leadership

Visit the sPCMA website at spcma.org



Download the sPCMA White Paper: The Management of Specialty Drugs

Visit the "Knowledge Center" to review card stacks about the specialty pharmacy industry





sPCMA

A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2017

March 8 & 9
HILTON BONNET CREEK
ORLANDO, FL

SAVE-THE-DATE



A DIVISION OF THE
Pharmaceutical Care
Management Association

spcmanet.org